F. Liu Central South University (CSU) Changsha (China)
Dr. Liu is an Assistant Professor of the Department of neurosurgery, Xiangya Hospital, centered on brain tumor therapeutics, brain organoid research, and drug screening. His doctoral training was in Neurosurgery at Central South University, and stem cell research in Houston Methodist Research Institute, Cornell University. A major goal of his research is basic-translation-clinical research by utilizing in vitro and in vivo cultured and primary models of the brain to study the molecular pharmacology and mechanisms of glioma and neuropsychiatric diseases pathogenesis. He published more than 11 original papers on identifying molecular markers in brain diseases and drug screening using brain organoid models.
J. Xu Shenzhen University Shenzhen (China)
Dr. Jianyong Xu obtained his Ph.D. degree (in 2016) in the field of Medicine from The University of Hong Kong, Hong Kong. Dr. Xu is currently working as Assistant Professor, in the School of Medicine, at Shenzhen University, Shenzhen, China. His research interests mainly lie in the subject areas/fields of stem cell biology, genome editing, gene therapy and their therapeutic applications. Dr. Xu, as an author/co-author, has published more than 20 manuscripts in various journals of international repute, and his documents have received over 2,290 citations.
H. Zhou Chinese PLA General Hospital Beijing (China)
Dr. Hao Zhou is a cardiologist in Chinese PLA General Hospital, focusing on the pathology and
treatment of acute/chronic cardiorenal damage such as myocardial infarction, cardiorenal syndrome
and diabetic cardiomyopathy. After vigorous training in University of Wyoming, Dr. Zhou have
acquired the basic experimental techniques involved in molecular/cellular biology and physiological
testing. His major area of research is focused on cardiac pathophysiology in acute reperfusion injury,
diabetes, obesity and aging. His laboratory in PLA general hospital is well versed with molecular
biology techniques including oxidative stress, mitochondrial function, autophagy and apoptosis. Much
of his current focuses are on the pathophysiological consequence of cardiac ischemia-reperfusion
injury on metabolic and mitochondrial functions. The goal of his research is to better understand the
pathogenesis of cardiac diseases as well as to develop strategies (such as melatonin and SGLT2i) to
lessen myopathic disorders under these conditions. He has gained broad training and background in
clinical cardiology and experimental cardiac physiology. He has extensive experience in cardiac
function and structure assessment with an emphasis on mitophagy function and mitochondrial stress-
related myocardial damage. As PI on several grants, he has successfully administered many research
projects and collaborated with other researchers.
Liang Cheng College of Bioinformatics Science and Technology Harbin Medical University Harbin, Heilongjiang (China)
Dr. Cheng obtained a doctorate (Ph.D.) in Bioinformatics from Harbin
Institute of Technology, Harbin, Heilongjiang, China. Currently Dr. Cheng
is a Professor and PI of Biological Software Engineering in Harbin Medical
University. He has published more than 70 scientific publications since
2013. Dr. Cheng develops novel algorithms and tools for gene therapy of
Type 2 Diabetes Mellitus and complex diseases.